Glutalytic Enzyme Blend
Also known as: Gluten-digesting enzyme blend, gluten protease blend, glutenase, Glutalytic Enzyme Blend
Overview
Glutalytic Enzyme Blend is a proprietary dietary supplement comprising a mixture of gluten-specific proteases, such as prolyl endopeptidases, and other proteolytic enzymes, typically derived from microbial or plant sources. Its primary function is to enzymatically break down gluten peptides, particularly gliadin, in the gastrointestinal tract. This action aims to mitigate gluten-induced symptoms in individuals with non-celiac gluten sensitivity (NCGS) or mild gluten intolerance. The supplement is taken orally with meals to degrade gluten before it can trigger adverse reactions. While research is emerging, it is crucial to note that Glutalytic Enzyme Blend is not intended as a treatment or substitute for a gluten-free diet in individuals with celiac disease.
Benefits
The primary benefit of Glutalytic Enzyme Blend is the reduction of immune responses to gluten and alleviation of gastrointestinal symptoms in individuals with non-celiac gluten sensitivity. A randomized controlled trial (RCT) involving 37 adults demonstrated a significant reduction in deamidated gliadin IgA antibodies (p=0.024) over 30 days, indicating a lowered immune response to gluten peptides. The same study also reported improvements in gastrointestinal reflux symptoms (p=0.038) and a decrease in food cravings (p=0.04). Another RCT with 30 subjects with NCGS showed that an enzyme mixture improved symptoms such as bloating, incomplete evacuation, and headaches. These benefits are observed in adults with self-reported gluten intolerance, excluding diagnosed celiac disease patients. While effect sizes are moderate and sample sizes are small, the statistically significant reductions in antibody levels and symptom scores suggest clinical relevance. Effects are typically observed within 30 days of daily supplementation.
How it works
Glutalytic Enzyme Blend functions by enzymatically hydrolyzing gluten peptides, specifically the proline-rich sequences found in gliadin, which are inherently resistant to human digestive enzymes. These enzymes act locally within the gastrointestinal tract, breaking down the complex gluten proteins into smaller, less antigenic fragments. By reducing the concentration of intact or partially digested gluten peptides in the gut lumen, the blend aims to decrease the immune activation and inflammatory responses that can be triggered in sensitive individuals. The enzymes target specific deamidated gliadin epitopes, preventing them from interacting with the intestinal lining and immune system in a way that causes symptoms. Systemic absorption of the enzymes is minimal, as their action is primarily confined to the digestive tract.
Side effects
Glutalytic Enzyme Blend is generally considered well-tolerated, with no serious adverse events reported in the available randomized controlled trials. No common (>5%), uncommon (1-5%), or rare (<1%) side effects have been specifically documented in the research. There are no known drug interactions, but caution is advised for individuals taking immunosuppressants or those with severe gastrointestinal disorders. It is explicitly contraindicated for individuals with diagnosed celiac disease, as it does not replace the necessity of a strict gluten-free diet for managing this autoimmune condition. The safety of Glutalytic Enzyme Blend in special populations, such as children, pregnant women, or lactating women, has not been established through research.
Dosage
In the primary study on Glutalytic™, an effective dosage was identified as 3 capsules daily, taken with meals, over a 30-day period. The exact enzyme units within this dosage were not specified. Optimal dosage ranges for Glutalytic Enzyme Blend are not yet well-established, and recommendations may vary depending on specific product formulations. There is no defined maximum safe dose, as no adverse effects have been reported at the studied dosages. For maximal enzymatic activity and efficacy, the supplement should be taken concurrently with meals that contain gluten. The enzymes are typically available in oral capsule or tablet forms. Their effectiveness is influenced by factors such as gastric pH and proper timing with food intake, ensuring the enzymes are present when gluten is consumed.
FAQs
Is Glutalytic Enzyme Blend safe for celiac disease?
No, it is not a substitute for a gluten-free diet in celiac patients. It is intended for individuals with non-celiac gluten sensitivity.
How quickly does it work?
Symptom improvement and a reduction in immune markers (deamidated gliadin IgA antibodies) have been observed within 30 days of daily supplementation.
Can it prevent gluten-induced damage?
Evidence suggests it can reduce immune markers and symptoms, but it does not prevent mucosal healing in celiac disease or fully mitigate damage.
Is it effective for all gluten sensitivities?
Most evidence supports its use in non-celiac gluten sensitivity. Its efficacy in other populations or conditions is less clear.
Are there side effects?
No significant side effects have been reported in clinical trials. It is generally considered well-tolerated.
Research Sources
- https://www.longdom.org/open-access-pdfs/tolerance-and-efficacy-of-glutalytic-a-randomized-doubleblind-placebocontrolled-study-2155-9600-1000727.pdf – This randomized, double-blind, placebo-controlled study evaluated the tolerance and efficacy of Glutalytic™ in 37 adults. It found significant reductions in deamidated gliadin IgA antibodies, gastrointestinal reflux symptoms, and food cravings over 30 days, indicating potential benefits for gluten-sensitive individuals. The study concluded that Glutalytic™ was well-tolerated.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6143542/ – This randomized controlled trial investigated the effects of a combination of gluten-digesting enzymes in 30 subjects with non-celiac gluten sensitivity (NCGS). The enzyme mixture significantly improved NCGS symptoms such as bloating and headaches compared to placebo, with no reported adverse events. The study supports the potential of enzyme blends for symptom management in NCGS.
- https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2017.00621/full – This systematic review and meta-analysis focused on re-challenge studies in non-celiac gluten sensitivity (NCGS). It established a correlation between gluten dose/duration and symptom relapse, highlighting the need for effective gluten degradation strategies. While not directly testing enzyme blends, it provides indirect evidence supporting the rationale for gluten-digesting enzymes.
- https://www.scirp.org/journal/paperinformation?paperid=82563 – This source discusses the general safety and efficacy of enzyme supplements, particularly in the context of digestive health. It supports the notion that enzyme blends can be well-tolerated and contribute to improved digestion, aligning with the safety profile observed for Glutalytic Enzyme Blend.
- https://celiac.org/a-gluten-digesting-enzyme-passes-phase-1-trial/ – This article from the Celiac Disease Foundation discusses a gluten-digesting enzyme passing a Phase 1 trial. While not specific to Glutalytic, it highlights the ongoing research and development in the field of enzymatic gluten degradation and the potential for such therapies, particularly for accidental gluten exposure.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7400306/ – This article provides further context on the mechanisms and potential applications of enzymes in managing gluten sensitivity. It reinforces the understanding that these enzymes work by breaking down gluten peptides, thereby reducing their immunogenicity and potential to cause symptoms in susceptible individuals.